Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2141-2160 of 3,900 trials

Colon Cancer: Neoadjuvant Dostarlimab Treatment

We are studying the effects of Dostarlimab in patients with untreated Stage III colon cancer. This trial aims to understand how well the treatment works and its safety before surgery.

Resectable Colon Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Advanced Cancer: BI 1831169 and Anti-PD-1 Therapy

We are testing different doses of a new medication alone and with an anti-PD-1 antibody for people with advanced solid tumors. This study aims to see how well these treatments work together.

Solid Tumors>2 yearsSafety phase (I)Oncology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

GRT7040: First-in-Human Safety Study

We are testing a new medication called GRT7040 in healthy volunteers to see how safe it is and how the body processes it. This study aims to gather important information before it can be used in patients.

Pain6-12 monthsSafety phase (I)AllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyHepatologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Triple-Negative Breast Cancer: NECVAX-NEO1 Treatment

We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.

Triple Negative Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Locally Recurrent Rectal Cancer: Induction Chemotherapy Study

We are comparing the effects of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone for patients with locally recurrent rectal cancer. This study aims to see which approach leads to better surgical outcomes and survival rates.

Recurrent Rectal CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Botox for Inability to Belch

We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.

Esophageal Disorders>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyOtolaryngology

MSC Therapy for Kidney Transplant Recipients

We are exploring whether a new therapy using stem cells can improve health outcomes for people who have received a kidney transplant. This study aims to understand its potential benefits in this patient group.

Kidney Transplant RejectionBiopsy-Proven Acute Rejection (BPAR)1-2 yearsSafety phase (I)Internal MedicineNephrology

Major Depressive Disorder: Ketamine and ECT Study

We are investigating whether combining ketamine with electroconvulsive therapy helps people with treatment-resistant depression. The study also examines its effects on brain chemicals and cognitive function.

Treatment Resistant DepressionMajor Depressive Disorder1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPsychiatry

Wheezing in Young Children: Oral Prednisolone Study

We are investigating whether oral prednisolone helps children under 2 years old with wheezing caused by rhinovirus. This study aims to find out if it improves their breathing and overall comfort.

Rhinovirus-induced WheezingMonitoring phase (IV)Standard MedicinesPediatricsPulmonology

Bladder Cancer: ONCOFID-P-B Treatment Study

We are studying a new treatment called ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to standard care. The goal is to see if this treatment can effectively reduce tumors and improve patient outcomes.

Bladder Cancer in Situ1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Muscle-Invasive Bladder Cancer: Erdafitinib Treatment Study

We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Gene Therapy for Hearing Loss: AAVAnc80-hOTOF

We are studying a new gene therapy for people with hearing loss due to Otoferlin gene mutations. The trial aims to assess the long-term safety and effectiveness of this treatment.

Otoferlin Gene-Mediated Hearing Loss>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOtolaryngology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Azithromycin for Hospitalized Children with Asthma Symptoms

We are studying whether a three-day treatment with azithromycin helps young children aged 1-5 years who are hospitalized due to asthma-like symptoms. This research may lead to better, personalized treatments based on individual responses.

Childhood Asthma>2 yearsEfficacy phase (II)Investigational MedicinesPediatricsPulmonology

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology